Problem

Clinical trials are operationally complex and vulnerable to missed risks across site enrollment, monitoring visits, significant study events, regulatory renewals, and closeout. Phases is aimed at the resulting operational burden: weak oversight can reduce trial performance, compromise data quality, and make audit readiness harder. The available research does not quantify the financial cost, but the core economic value is preventing execution problems before they create delays, rework, or compliance exposure. Its clearest initial use case is overseeing patient recruitment and trial-site execution continuously rather than relying only on periodic manual reviews.

Product / Service

Phases deploys AI agents to oversee clinical trials, identify risks, and take actions to resolve issues. Its product appears to function as an always-on layer of study oversight: the public demonstration shows agents tracking trial zones and milestones such as site enrollment, monitoring visits, IRB or IEC renewals, significant study events, and monitoring closeout. This positions Phases as more than a reporting dashboard, with the intended benefit of improving operational performance, data quality, and audit readiness through automated detection and follow-through.

Market

Phases competes in clinical-trial operations and oversight software, specifically the emerging category of AI agents for pharmaceutical companies, contract research organizations, and research sites. The company is explicitly seeking relationships with people running trials in those three segments. No named competitors are identified in the available research, so the most relevant competitive alternatives are likely existing manual oversight processes and conventional clinical-trial management or monitoring tools rather than a documented set of direct AI rivals.

Phases is an early-stage company founded in 2025 and listed as an active Summer 2025 Y Combinator company with a three-person team. It has a public product site, a working-style study oversight demonstration, and a call to book a demo, while a separate startup profile describes its initial product focus as automating clinical trials with AI agents beginning in patient recruitment. The available evidence does not disclose revenue, customer counts, or deployed-trial metrics, so it should be treated as early commercial-stage or pre-revenue for diligence purposes rather than as a company with publicly demonstrated scale.